aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Exact Sciences Corp., founded in the United States, is dedicated to developing non-invasive molecular screening tests for early cancer detection, with a primary focus on colorectal cancer. Their flagship product, a stool-based DNA test, identifies genetic mutations associated with pre-cancer and cancer cells, aiming to catch the disease at its earliest stages. The company's vision is to eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment, thereby improving patient outcomes and saving lives.
Notable figures affiliated with Exact Sciences include key researchers and medical professionals who have contributed to the development of their innovative diagnostic tools. The company has garnered significant investment and support from the healthcare sector, reflecting confidence in its mission and technology. Key achievements include the successful commercialization of their colorectal cancer screening test and ongoing advancements in their diagnostic pipeline. Exact Sciences has made a substantial impact on cancer detection and prevention, positioning itself as a leader in the field of molecular diagnostics.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Diagnostics
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
United States
When was Exact Sciences founded?
Exact Sciences was founded in 1995.
Where is Exact Sciences’s headquarters located?
Exact Sciences’s headquarters is located in Tokyo, JP.
When was Exact Sciences’s last funding round?
Exact Sciences’s most recent funding round was for $500M (USD) in February 2023.
How many employees does Exact Sciences have?
Exact Sciences has 6400 employees as of Feb 6, 2024.
How much has Exact Sciences raised to-date?
As of July 05, 2023, Exact Sciences has raised a total of $2.1B (USD) since Feb 23, 2023.
Add Comparison
Total Raised to Date
$2.1B
USD
Last Update Feb 23, 2023
Last Deal Details
$500M
USD
Feb 23, 2023
Post Ipo Debt
Total Employees Over Time
6400
As of Feb 2024
Exact Sciences Address
Tokyo,
100-0005
Japan
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts